Advanced searches left 3/3

Vitamin K - PubMed

Summarized by Plex Scholar
Last Updated: 09 August 2022

* If you want to update the article please login/register

A non-canonical vitamin K cycle is a potent ferroptosis suppressor.

Although substantial progress has been made in determining cell sensitivity toward ferroptosis, cell-extrinsic and cell-intrinsic reactions that determine cell sensitivity toward ferroptosis remain unclear. Vitamin K deficiency was also responsible for the antidotal effects of vitamin K against warfarin poisoning, thanks to FSP1-mediated vitamin K supplementation. According to FSP1, the enzyme mediating warfarin-resistant vitamin K reduction in the canonical vitamin K cycle6 has been reduced.

Source link: https://doi.org/10.1038/s41586-022-05022-3


Vitamin K content of cheese, yoghurt and meat products in Australia.

Vitamin K content of Australian foods is limited, thus preventing the estimation of vitamin K intakes in the Australian population. The highest mean concentrations of PK, MK-4, and MK-9 were discovered in lamb liver, chicken leg meat, and Cheddar cheese, respectively. MK-8 was only discovered in Cheddar cheese, not MK-8. As the K vitamer profile and concentrations appear to vary largely by geographic location, Australia needs a vitamin K food composition database that is representative of Australian foods.

Source link: https://doi.org/10.1016/j.foodchem.2022.133772


Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.

In the secondary prevention of thrombosis in APS patients, data comparing direct oral anticoagulants to Vitamin K antagonists is still conflicting. In treating patients with APS, we intend to review and analyze literature on DOAC's effectiveness and safety relative to VKAs. Patients receiving VKAs had an elevated risk of recurrent thrombosis [risk ratio: 3. 68, 95% confidence interval : 1. 49-8. 93; I2= 29 percent, P= 0. 005] compared to those using VKAs. Upon administering DOACs or VKAs in low-risk APS patients, a similar risk of recurrent thrombosis or major bleeding was reported. Overall APS patients, Rivaroxaban usage was attributed to a high risk of recurrent thromboses, particularly recurrent arterial thromboses. In the absence of contraindications, this meta-analysis shows that VKAs remain the first-choice treatment for high-risk APS patients, with DOACs being the more appropriate option for low-risk APS patients.

Source link: https://doi.org/10.1097/MBC.0000000000001153


The Role of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Atrial Fibrillation: Treatment Management Based on Patient and Drug Characteristics.

According to several factors, including treatment adherence problems, unwillingness to follow guideline guidelines, poor feedback on the use of new drugs, medication prices, and payment conditions, in Turkey, atrial fibrillation patient percentage under good anticoagulation therapy is less than in other countries. In three separate meetings to identify the review topics and analyze the results of the systematic literature review, a gastroenterologist, 2 neurologists, and 11 cardiologists from university and training hospitals in Turkey who are experienced in atrial fibrillation and non-vitamin K antagonist oral anticoagulant therapy met in three separate meetings to determine the study objectives and analyze the results of the systematic literature search. Although Turkish patients with atrial fibrillation have been reported to be younger, they are more likely to have coexisting cardiovascular disorders than those in other countries.

Source link: https://doi.org/10.5543/tkda.2022.21191


Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: A single center retrospective cohort study.

Patients with a BMI of at least 40 kg/m2 who were admitted to Emory University Hospital from January 2012 to May 2020 with acute VTE, and then embarked on anticoagulation therapy with either DOAC or VKA. A multivariate Cox proportional hazard regression was used to determine the likelihood of VTE recurrence among morbidly obese patients. Conclusions: There were 247 morbidly obese patients who were more likely than non-obese patients to be younger, female, and of non-white ethnicity. The risk of experiencing a recurrent thrombosis was not significantly different among morbidly obese patients treated with a DOAC compared to VKA compared to VKA. These results confirm that morbidly obese patients receiving DOAC or VKA have similar risks of recurrent VTE in morbidly obese people.

Source link: https://doi.org/10.1002/jha2.418

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions